Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directionsRiccardo Gerosa, Alberto Zambelli, Rita De Sanctis et al.|Critical Reviews in Oncology/Hematology|2024Cited by 87
Digital innovations in breast cancer care: exploring the potential and challenges of digital therapeutics and clinical decision support systemsFlavia Jacobs, Alberto Zambelli, Matteo Giovanni Della Porta et al.|Digital Health|2024Cited by 14
Ribociclib-Induced Cutaneous Adverse Events in Metastatic HR+/HER2− Breast Cancer: Incidence, Multidisciplinary Management, and Prognostic ImplicationRiccardo G. Borroni, Rita De Sanctis, Michela Bartolini et al.|The Oncologist|2024Cited by 9
Charting the Course in Sequencing Antibody-Drug Conjugates in Breast CancerGiuseppe Saltalamacchia, Alberto Zambelli, Rosalba Torrisi et al.|Biomedicines|2024Cited by 9
Common Misconceptions about Diet and Breast Cancer: An Unclear Issue to DispelAnastasia Lalioti, Rita De Sanctis, Laura Verzeletti et al.|Cancers|2024Cited by 5